Cargando…

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study

INTRODUCTION: Oxycodone ARIR is a novel oral, abuse-deterrent, immediate-release (IR) formulation with physical and chemical properties that deter misuse and abuse by non-oral routes. In this single-dose pharmacokinetic study, we assessed the relative bioavailability of oxycodone for Oxycodone ARIR...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, Lynn R., Kinzler, Eric R., Pantaleon, Carmela, Iverson, Matthew, Aigner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824394/
https://www.ncbi.nlm.nih.gov/pubmed/31065992
http://dx.doi.org/10.1007/s12325-019-00963-0
_version_ 1783464733051977728
author Webster, Lynn R.
Kinzler, Eric R.
Pantaleon, Carmela
Iverson, Matthew
Aigner, Stefan
author_facet Webster, Lynn R.
Kinzler, Eric R.
Pantaleon, Carmela
Iverson, Matthew
Aigner, Stefan
author_sort Webster, Lynn R.
collection PubMed
description INTRODUCTION: Oxycodone ARIR is a novel oral, abuse-deterrent, immediate-release (IR) formulation with physical and chemical properties that deter misuse and abuse by non-oral routes. In this single-dose pharmacokinetic study, we assessed the relative bioavailability of oxycodone for Oxycodone ARIR and IR oxycodone, and the effect of food on Oxycodone ARIR following oral administration. METHODS: This open-label, randomized study in healthy adults compared the relative bioavailability of Oxycodone ARIR 30 mg to IR oxycodone 30 mg under fasted conditions, and Oxycodone ARIR under fed versus fasted conditions. Pharmacokinetic parameters included area under the concentration–time curve from time 0 to the last measured concentration (AUC(0–t)) and the maximum oxycodone plasma concentration (C(max)). Equivalence was determined using an analysis of variance of the least-squares means. RESULTS: Fifty-eight subjects completed the study. Under fasted conditions, AUC(0–t) was 4% lower (90% CI 92.5–98.7%) and mean C(max) was 14% lower (90% CI 78.8–94.3%) for Oxycodone ARIR versus IR oxycodone. AUC(0–t) was 23% higher (90% CI 119.1–127.0%) and mean C(max) was higher (90% CI 108.6–129.4%) when Oxycodone ARIR was administered in the fed versus fasted state. Common adverse events included nausea, headache, and dizziness. CONCLUSION: In this single-dose pharmacokinetic evaluation, fasted Oxycodone ARIR 30 mg had similar bioavailability to and is expected to have the same efficacy and safety profile as IR oxycodone. When administered in the fed state, pharmacokinetic parameters were slightly higher; however, these differences were considered not clinically meaningful and show that Oxycodone ARIR can be administered with or without food. FUNDING: This study was funded by Inspirion Delivery Sciences, LLC. Daiichi Sankyo, Inc. funded the journal’s article processing charges and open access fee. PLAIN LANGUAGE SUMMARY: Plain language summary available for this article.
format Online
Article
Text
id pubmed-6824394
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68243942019-11-06 Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study Webster, Lynn R. Kinzler, Eric R. Pantaleon, Carmela Iverson, Matthew Aigner, Stefan Adv Ther Original Research INTRODUCTION: Oxycodone ARIR is a novel oral, abuse-deterrent, immediate-release (IR) formulation with physical and chemical properties that deter misuse and abuse by non-oral routes. In this single-dose pharmacokinetic study, we assessed the relative bioavailability of oxycodone for Oxycodone ARIR and IR oxycodone, and the effect of food on Oxycodone ARIR following oral administration. METHODS: This open-label, randomized study in healthy adults compared the relative bioavailability of Oxycodone ARIR 30 mg to IR oxycodone 30 mg under fasted conditions, and Oxycodone ARIR under fed versus fasted conditions. Pharmacokinetic parameters included area under the concentration–time curve from time 0 to the last measured concentration (AUC(0–t)) and the maximum oxycodone plasma concentration (C(max)). Equivalence was determined using an analysis of variance of the least-squares means. RESULTS: Fifty-eight subjects completed the study. Under fasted conditions, AUC(0–t) was 4% lower (90% CI 92.5–98.7%) and mean C(max) was 14% lower (90% CI 78.8–94.3%) for Oxycodone ARIR versus IR oxycodone. AUC(0–t) was 23% higher (90% CI 119.1–127.0%) and mean C(max) was higher (90% CI 108.6–129.4%) when Oxycodone ARIR was administered in the fed versus fasted state. Common adverse events included nausea, headache, and dizziness. CONCLUSION: In this single-dose pharmacokinetic evaluation, fasted Oxycodone ARIR 30 mg had similar bioavailability to and is expected to have the same efficacy and safety profile as IR oxycodone. When administered in the fed state, pharmacokinetic parameters were slightly higher; however, these differences were considered not clinically meaningful and show that Oxycodone ARIR can be administered with or without food. FUNDING: This study was funded by Inspirion Delivery Sciences, LLC. Daiichi Sankyo, Inc. funded the journal’s article processing charges and open access fee. PLAIN LANGUAGE SUMMARY: Plain language summary available for this article. Springer Healthcare 2019-05-07 2019 /pmc/articles/PMC6824394/ /pubmed/31065992 http://dx.doi.org/10.1007/s12325-019-00963-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Webster, Lynn R.
Kinzler, Eric R.
Pantaleon, Carmela
Iverson, Matthew
Aigner, Stefan
Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title_full Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title_fullStr Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title_full_unstemmed Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title_short Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
title_sort relative oral bioavailability of an abuse-deterrent, immediate-release formulation of oxycodone, oxycodone arir in a randomized study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824394/
https://www.ncbi.nlm.nih.gov/pubmed/31065992
http://dx.doi.org/10.1007/s12325-019-00963-0
work_keys_str_mv AT websterlynnr relativeoralbioavailabilityofanabusedeterrentimmediatereleaseformulationofoxycodoneoxycodonearirinarandomizedstudy
AT kinzlerericr relativeoralbioavailabilityofanabusedeterrentimmediatereleaseformulationofoxycodoneoxycodonearirinarandomizedstudy
AT pantaleoncarmela relativeoralbioavailabilityofanabusedeterrentimmediatereleaseformulationofoxycodoneoxycodonearirinarandomizedstudy
AT iversonmatthew relativeoralbioavailabilityofanabusedeterrentimmediatereleaseformulationofoxycodoneoxycodonearirinarandomizedstudy
AT aignerstefan relativeoralbioavailabilityofanabusedeterrentimmediatereleaseformulationofoxycodoneoxycodonearirinarandomizedstudy